Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 25Terminated 16Withdrawn 6Active not recruiting 4Recruiting 2Unknown 1Suspended 1

Sponsor Class

OTHER 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 6Dermatologic 6Other hematologic neoplasm 5Lymphoid 2Thoracic 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 3Melanoma 2Neoplasm Metastasis 1Kidney Neoplasms 1Invasive Bladder Cancer Stage IV 1Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Interleukin-2 × Genitourinary × Clear all
NCT01355562 2020-04-30

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Loma Linda University

Phase 2 Withdrawn
DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT03111901 2019-07-12

UVA-AM-002

University of Virginia

Phase 1/2 Withdrawn
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02863913 2019-03-06

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Peking University

Phase 1 Withdrawn
Genitourinary

Invasive Bladder Cancer Stage IV

NCT02867332 2019-03-06

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Peking University

Phase 1 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT02867345 2019-03-06

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Peking University

Withdrawn
Genitourinary

Hormone Refractory Prostate Cancer

NCT03226236 2018-11-13

RENALVax-2

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡